Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes
Vertex Pharmaceuticals Inc VRTX
News
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Vertex to Participate in Upcoming September Investor Conferences
Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint
Vertex Pharmaceuticals Bumps Up Fiscal Year Outlook on Growth of Cystic Fibrosis Drugs
Vertex Reports Second Quarter 2026 Financial Results
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021 — Data Talk
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
Cantor Sees 'Clear Strategic Rationale' Behind Vertex's Buy of Crinetics — Market Talk
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
Vertex to Acquire Crinetics Pharmaceuticals
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Gets FDA OK for Sickle Cell Disease Treatment in Young Children
Vertex Pharmaceuticals Says New Pain Management Drug Is Under Review at Health Canada
Vertex Pharmaceuticals Ends Study of Cystic Fibrosis Drug Over Tolerability Issues
Vertex Pharmaceuticals Posts Higher 1Q Profit
Vertex Pharmaceuticals Up Over 9%, on Pace for Largest Percent Increase Since December 2023 — Data Talk
United States